Drug Trial Radar · NCT06574997
Expanded Access Program for RP in Adults
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
No longer available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- OcugenIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2024
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years, up to 99 years
Summary
As written by the sponsor on the registry.
This intermediate-size patient population expanded access program is to provide access to investigational product OCU400 for up to 75 patients with Retinitis Pigmentosa (RP) outside of the ongoing clinical trial Phase 3 program for patients who do not have access to alternative Food and Drug Administration (FDA)-approved products for treatment of the disease.
Conditions
- Retinitis Pigmentosa
Interventions
OCU400Drug
Participants will receive a subretinal injection of OCU400 modifier gene therapy product.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Associated Retina Consultants
Phoenix, Arizona
Advanced Research
Deerfield Beach, Florida
Erie Retina Research
Erie, Pennsylvania
Valley Retina Institute
McAllen, Texas
Gundersen Health
La Crosse, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.